Drug intelligence / Profile preview

αv integrin shRNA

Development stage
Preclinical
Lead developer
Oregon Health & Science University
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

αv integrin shRNA is an experimental RNA interference (RNAi) agent designed to specifically silence the expression of the αv integrin subunit (ITGAV). Delivered via lentiviral vectors in preclinical studies, this short hairpin RNA (shRNA) mediates the degradation of αv integrin mRNA, leading to a significant reduction in protein levels. In metastatic melanoma models, such as the A2058 cell line, knockdown of αv integrin has been shown to inhibit cell proliferation, disrupt adherent growth, and markedly reduce the migration and invasive capacity of tumor cells. This research tool is primarily used to elucidate the role of integrin-mediated cell-extracellular matrix (ECM) interactions in the metastatic cascade and to validate αv integrin as a therapeutic target in aggressive cancers.

Other names
anti-αv integrin shRNAintegrin alpha V shRNAITGAV shRNA
02

Targets

Innate immune RNA sensorsITGAV (Integrin αV)Integrin subunit alpha V (ITGAV) mRNA

Beyond the preview

Go deeper on αv integrin shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on αv integrin shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call